DK2421982T3 - Fremgangsmåde til fremstilling af rekombinante polyomavirale vektorpartikler. - Google Patents

Fremgangsmåde til fremstilling af rekombinante polyomavirale vektorpartikler. Download PDF

Info

Publication number
DK2421982T3
DK2421982T3 DK10716326.3T DK10716326T DK2421982T3 DK 2421982 T3 DK2421982 T3 DK 2421982T3 DK 10716326 T DK10716326 T DK 10716326T DK 2421982 T3 DK2421982 T3 DK 2421982T3
Authority
DK
Denmark
Prior art keywords
antigen
polyomavirus
polyomaviral
cells
functional
Prior art date
Application number
DK10716326.3T
Other languages
English (en)
Inventor
De Walter Gerhardus Vries
Original Assignee
Amarna Holding B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amarna Holding B V filed Critical Amarna Holding B V
Application granted granted Critical
Publication of DK2421982T3 publication Critical patent/DK2421982T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22051—Methods of production or purification of viral material
    • C12N2710/22052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (8)

1. Fremgangsmåde til fremstilling af rekombinante polyomavirale vektorpartikler, der ikke koder for et funktionelt polyomaviralt lille T-antigen, som omfatter trinene a. Tilvejebringelse af en cellelinje, der er permissiv for vildtypepolyomavirus, hvilken cellelinje omfatter et gen, der koder for et funktionelt polyomaviralt stort T-antigen, der er stabilt integreret i cellens genom, hvor cellelinjen ikke omfatter et gen, der koder for et funktionelt polyomaviralt lille T-antigen, b. Indførelse i cellelinjen af et polyomavirus-DNA, der ikke koder for et funktionelt polyomaviralt lille T-antigen og endvidere ikke koder for et funktionelt stort T-antigen, c. Dyrkning af cellerne i et vækstmedium under betingelser, hvor cellelinjen danner det store T-antigen i trans, og der åbner mulighed for dannelse af rekombinante polyomavirale vektorpartikler, og d. Høst af de rekombinante polyomavirale vektorpartikler fra cellekulturen.
2. Sammensætning, der omfatter mere end én million rekombinante polyomavirale vektorpartikler, der ikke koder for et funktionelt polyomaviralt lille T-antigen og endvidere ikke koder for et stort T-antigen, hvilke polyomaviruspartikler er ude af stand til at replikere i celler, der er permissive for vildtypepolyomavirusset, der er kendetegnet ved, at sammensætningen ikke indeholder en enkel polyomaviruspartikel, der er i stand til at replikere i celler, der er permissive for vildtypepolyomavirusset, hvor cellerne ikke udtrykker et funktionelt polyomaviralt stort T-antigen.
3. Sammensætning ifølge krav 2, hvor polyomavirusset er et primatpolyomavirus.
4. Sammensætning ifølge krav 3, hvor polyomavirusset er et abepolyomavirus.
5. Sammensætning ifølge krav 4, hvor polyomavirusset er udvalgt fra gruppen, der består af SV40, SV12, lymfotropisk polyomavirus, polyomavirus fra afrikansk grøn abe og chimpansepolyomavirus.
6. Sammensætning ifølge krav 5, hvor polyomavirusset er SV4 0 .
7. Cellelinje, der er permissiv for et polyomavirus, der omfatter rekombinante polyomavirale vektorpartikler, der ikke omfatter et gen, der koder for et funktionelt polyomaviralt lille T-antigen og endvidere ikke omfatter et gen, der koder for et funktionelt stort T-antigen, hvilken cellelinje omfatter et gen, der er stabilt integreret i cellens genom, der koder for et funktionelt polyomaviralt stort T-antigen, og ikke omfatter et gen, der koder for et funktionelt polyomaviralt lille T-antigen.
8. Sammensætning ifølge kravene 2 til 6 til anvendelse som et medikament.
DK10716326.3T 2009-04-22 2010-04-22 Fremgangsmåde til fremstilling af rekombinante polyomavirale vektorpartikler. DK2421982T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09158498A EP2243836A1 (en) 2009-04-22 2009-04-22 Method for the production of recombinant polymavirus vector particles
PCT/EP2010/055330 WO2010122094A1 (en) 2009-04-22 2010-04-22 Method for the production of recombinant polyomaviral vector particles

Publications (1)

Publication Number Publication Date
DK2421982T3 true DK2421982T3 (da) 2015-10-05

Family

ID=40983547

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10716326.3T DK2421982T3 (da) 2009-04-22 2010-04-22 Fremgangsmåde til fremstilling af rekombinante polyomavirale vektorpartikler.

Country Status (13)

Country Link
US (1) US9587226B2 (da)
EP (2) EP2243836A1 (da)
JP (1) JP5756795B2 (da)
KR (1) KR101813723B1 (da)
CN (1) CN102695800B (da)
AU (1) AU2010240900B2 (da)
BR (1) BRPI1016173A2 (da)
CA (1) CA2759596C (da)
DK (1) DK2421982T3 (da)
EA (1) EA022206B1 (da)
ES (1) ES2548990T3 (da)
MX (1) MX2011010612A (da)
WO (1) WO2010122094A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2314707A1 (en) * 2009-10-26 2011-04-27 Amarna Therapeutics B.V. Method for the expression of a recombinant protein in a mammalian cell
WO2014008382A1 (en) * 2012-07-05 2014-01-09 Vertex Pharmaceuticals Incorporated Materials and methods for jc polyomavirus propagation and detection
US20160287685A1 (en) * 2013-11-22 2016-10-06 Amarna Holding B.V. Method for restoring immune tolerance in vivo
WO2015118146A1 (en) 2014-02-10 2015-08-13 Univercells Nv System, apparatus and method for biomolecules production
CN105780797A (zh) 2014-12-26 2016-07-20 深圳市博德维环境技术有限公司 气膜建筑及其基础
NL2030945B1 (en) 2022-02-15 2023-08-21 Amarna Holding B V Polyomaviral gene delivery vector particle comprising a nucleic acid sequence encoding a phosphatase activity-possessing polypeptide
NL2033264B1 (en) 2022-10-10 2024-04-26 Amarna Holding B V Composition and method for the production of polyomaviral vector particles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027123A2 (en) * 1997-11-26 1999-06-03 Board Of Regents, The University Of Texas System Modified sv40 viral vectors
IL145463A0 (en) 2001-09-16 2002-06-30 Yissum Res Dev Co A packaging complementation cell-line for sv40 vectors
CN100577808C (zh) * 2003-09-09 2010-01-06 艾塞特生物技术有限公司 利用多瘤病毒和eb病毒序列的啮齿动物表达系统
AU2004270765B2 (en) 2003-09-09 2010-03-04 Acyte Biotech Pty Ltd Rodent expression systems utilising Polyoma Virus and Epstein Barr Virus sequences
GB2439543A (en) 2006-06-27 2008-01-02 Viruvation B V Polyoma viral vector production cell lines and nucleic acids expressing dsRNA viral sequences

Also Published As

Publication number Publication date
AU2010240900B2 (en) 2015-06-11
KR20120006062A (ko) 2012-01-17
MX2011010612A (es) 2012-01-12
EP2243836A1 (en) 2010-10-27
EP2421982B1 (en) 2015-07-01
EA201101532A1 (ru) 2012-04-30
JP5756795B2 (ja) 2015-07-29
BRPI1016173A2 (pt) 2019-10-01
CN102695800B (zh) 2015-11-25
CA2759596C (en) 2017-08-01
WO2010122094A1 (en) 2010-10-28
US9587226B2 (en) 2017-03-07
JP2012524531A (ja) 2012-10-18
CA2759596A1 (en) 2010-10-28
US20120040399A1 (en) 2012-02-16
AU2010240900A1 (en) 2011-10-20
EA022206B1 (ru) 2015-11-30
ES2548990T3 (es) 2015-10-22
KR101813723B1 (ko) 2017-12-29
CN102695800A (zh) 2012-09-26
EP2421982A1 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
DK2421982T3 (da) Fremgangsmåde til fremstilling af rekombinante polyomavirale vektorpartikler.
JP6093358B2 (ja) アデノ随伴ウイルスベクターの産生細胞
JP4495587B2 (ja) 組換えアデノウイルスベクターおよびその使用
US7790446B2 (en) Vectors, cell lines and their use in obtaining extended episomal maintenance replication of hybrid plasmids and expression of gene products
JP2020039340A (ja) ウイルスベクターの作製
EP2314707A1 (en) Method for the expression of a recombinant protein in a mammalian cell
US20220105164A1 (en) Method for Restoring Immune Tolerance In Vivo
US20100129913A1 (en) Polioma vector expressing long double-stranded rnas
KR20200101322A (ko) 진핵 세포주
US20050118699A1 (en) Packaging complementation cell-line for sv-40 vectors
WO2007005781A2 (en) Dna vector production system